Skip to main content
SpringerLink
Log in

CANCER METABOLISM

Exploiting KRAS-mediated metabolic reprogramming as a therapeutic target

  • News & Views
  • Published:

From Nature Genetics

View current issue Submit your manuscript

Half of all colorectal cancers bear KRAS-activating mutations that affect the metabolic dependencies of cancer cells and drive resistance to commonly used drugs. A new study provides insights into KRAS-driven metabolic rewiring and identifies a new therapeutic target for KRAS-mutant cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Loss of Slc7a5 attenuates Kras-driven tumor progression.

References

  1. Fearon, E. R. & Vogelstein, B. Cell 61, 759–767 (1990).

    Article  CAS  Google Scholar 

  2. The Cancer Genome Atlas Network. Nature 487, 330–337 (2012).

    Article  Google Scholar 

  3. Schwitalla, S. et al. Cell 152, 25–38 (2013).

    Article  CAS  Google Scholar 

  4. Haigis, K. M. et al. Nat. Genet. 40, 600–608 (2008).

    Article  CAS  Google Scholar 

  5. Verissimo, C. S. et al. eLife 5, e18489 (2016).

    Article  Google Scholar 

  6. Gimple, R. C. & Wang, X. Front. Oncol. 9, 965 (2019).

    Article  Google Scholar 

  7. Kimmelman, A. C. Clin. Cancer Res. 21, 1828–1834 (2015).

    Article  CAS  Google Scholar 

  8. Warburg, O. Science 123, 309–314 (1956).

    Article  CAS  Google Scholar 

  9. Smith, B. et al. Cell Rep. 17, 821–836 (2016).

    Article  CAS  Google Scholar 

  10. Ying, H. et al. Cell 149, 656–670 (2012).

    Article  CAS  Google Scholar 

  11. Najumudeen, A. K. et al. Nat. Genet. https://doi.org/10.1038/s41588-020-00753-3 (2020).

  12. Guinney, J. et al. Nat. Med. 21, 1350–1356 (2015).

    Article  CAS  Google Scholar 

  13. Canon, J. et al. Nature 575, 217–223 (2019).

    Article  CAS  Google Scholar 

  14. Hallin, J. et al. Cancer Discov. 10, 54–71 (2020).

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. These authors contributed equally: Sanne Bootsma, Sanne M. van Neerven.

Authors and Affiliations

  1. Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology and Metabolism, Amsterdam University Medical Centers, Amsterdam, the Netherlands

    Sanne Bootsma, Sanne M. van Neerven & Louis Vermeulen

  2. Oncode Institute Amsterdam, Amsterdam, the Netherlands

    Sanne Bootsma, Sanne M. van Neerven & Louis Vermeulen

Authors
  1. Sanne Bootsma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sanne M. van Neerven
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Louis Vermeulen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Louis Vermeulen.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bootsma, S., van Neerven, S.M. & Vermeulen, L. Exploiting KRAS-mediated metabolic reprogramming as a therapeutic target. Nat Genet 53, 9–10 (2021). https://doi.org/10.1038/s41588-020-00758-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41588-020-00758-y

  • Springer Nature America, Inc.

Search

Navigation